Ankylosing Spondylitis Treatment Market Research Report Information By Treatment (Drugs, Physical Therapy, Surgery and Others), By End User (Hospitals, Clinics, Ambulatory Surgery Centres and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Modality

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT

6.1. Overview

6.2. Drugs

6.3. Physical Therapy

6.4. Surgery

6.5. Others

7. GLOBAL ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER

7.1. Overview

7.2. Hospitals

7.3. Clinics

7.4. Ambulatory Surgery Centres

7.5. Others

8. GLOBAL ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY REGION

8.1. Overview

8.2. North America

8.2.1. U.S.

8.2.2. Canada

8.3. Europe

8.3.1. Germany

8.3.2. France

8.3.3. U.K

8.3.4. Italy

8.3.5. Spain

8.3.6. Rest of Europe

8.4. Asia-Pacific

8.4.1. China

8.4.2. India

8.4.3. Japan

8.4.4. South Korea

8.4.5. Australia

8.4.6. Rest of Asia-Pacific

8.5. Rest of the World

8.5.1. Middle East

8.5.2. Africa

8.5.3. Latin America

9. COMPETITIVE LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Global Ankylosing spondylitis treatment Market,

9.5. Competitive Benchmarking

9.6. Leading Players in Terms of Number of Developments in the Global Ankylosing spondylitis treatment Market,

9.7. Key developments and Growth Strategies

9.7.1. New TREATMENT Launch/END-USER Deployment

9.7.2. Merger & Acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix

9.8.1. Sales & Operating Income, 2022

9.8.2. Major Players R&D Expenditure. 2022

10. COMPANY PROFILES

10.1. AbbVie Inc

10.1.1. Company Overview

10.1.2. Financial Overview

10.1.3. Treatment Offered

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Janssen Pharmaceuticals Inc

10.2.1. Company Overview

10.2.2. Financial Overview

10.2.3. Treatment Offered

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. Pfizer Inc.

10.3.1. Company Overview

10.3.2. Financial Overview

10.3.3. Treatment Offered

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. Sandoz International GmbH

10.4.1. Company Overview

10.4.2. Financial Overview

10.4.3. Treatment Offered

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Amgen Inc.

10.5.1. Company Overview

10.5.2. Financial Overview

10.5.3. Treatment Offered

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. Protalix BioTherapeutics, Inc.

10.6.1. Company Overview

10.6.2. Financial Overview

10.6.3. Treatment Offered

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. Reliance Life Sciences Pvt. Ltd.

10.7.1. Company Overview

10.7.2. Financial Overview

10.7.3. Treatment Offered

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. Momenta Pharmaceuticals Inc

10.8.1. Company Overview

10.8.2. Financial Overview

10.8.3. Treatment Offered

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. Celgene Corporation

10.9.1. Company Overview

10.9.2. Financial Overview

10.9.3. Treatment Offered

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Regeneron Pharmaceuticals

10.10.1. Company Overview

10.10.2. Financial Overview

10.10.3. Treatment Offered

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

10.11. Merck & Co. Inc

10.11.1. Company Overview

10.11.2. Financial Overview

10.11.3. Treatment Offered

10.11.4. Key Developments

10.11.5. SWOT Analysis

10.11.6. Key Strategies

11. APPENDIX

11.1. References

11.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL ANKYLOSING SPONDYLITIS TREATMENT MARKET, SYNOPSIS, 2018-2032

TABLE 2 GLOBAL ANKYLOSING SPONDYLITIS TREATMENT MARKET, ESTIMATES & FORECAST, 2018-2032 (USD BILLION)

TABLE 3 GLOBAL ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 4 GLOBAL ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 5 NORTH AMERICA ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 6 NORTH AMERICA ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 7 NORTH AMERICA ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD BILLION)

TABLE 8 U.S. ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 9 U.S. ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 10 CANADA ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 11 CANADA ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 12 EUROPE ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 13 EUROPE ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 14 EUROPE ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD BILLION)

TABLE 15 GERMANY ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 16 GERMANY ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 17 FRANCE ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 18 FRANCE ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 19 ITALY ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 20 ITALY ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 21 SPAIN ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 22 SPAIN ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 23 U.K ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 24 U.K ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 25 REST OF EUROPE ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 26 REST OF EUROPE ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 27 ASIA PACIFIC ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 28 ASIA PACIFIC ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 29 ASIA PACIFIC ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD BILLION)

TABLE 30 JAPAN ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 31 JAPAN ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 32 CHINA ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 33 CHINA ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 34 INDIA ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 35 INDIA ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 36 AUSTRALIA ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 37 AUSTRALIA ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 38 SOUTH KOREA ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 39 SOUTH KOREA ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 40 REST OF ASIA-PACIFIC ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 41 REST OF ASIA-PACIFIC ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 42 REST OF WORLD ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 43 REST OF WORLD ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 44 REST OF WORLD ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD BILLION)

TABLE 45 MIDDLE EAST ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 46 MIDDLE EAST ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 47 AFRICA ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 48 AFRICA ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

TABLE 49 LATIN AMERICA ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 50 LATIN AMERICA ANKYLOSING SPONDYLITIS TREATMENT MARKET, BY END-USER, 2018-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL ANKYLOSING SPONDYLITIS TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL ANKYLOSING SPONDYLITIS TREATMENT MARKET

FIGURE 4 GLOBAL ANKYLOSING SPONDYLITIS TREATMENT MARKET, SHARE (%), BY TREATMENT, 2022

FIGURE 5 GLOBAL ANKYLOSING SPONDYLITIS TREATMENT MARKET, SHARE (%), BY END-USER, 2022

FIGURE 6 GLOBAL ANKYLOSING SPONDYLITIS TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 7 NORTH AMERICA: ANKYLOSING SPONDYLITIS TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 8 EUROPE: ANKYLOSING SPONDYLITIS TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 9 ASIA-PACIFIC: ANKYLOSING SPONDYLITIS TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 10 REST OF THE WORLD: ANKYLOSING SPONDYLITIS TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 11 GLOBAL ANKYLOSING SPONDYLITIS TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2022 (%)

FIGURE 12 ABBVIE INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 13 ABBVIE INC: SWOT ANALYSIS

FIGURE 14 JANSSEN PHARMACEUTICALS INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 15 JANSSEN PHARMACEUTICALS INC: SWOT ANALYSIS

FIGURE 16 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 PFIZER INC.: SWOT ANALYSIS

FIGURE 18 SANDOZ INTERNATIONAL GMBH: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 SANDOZ INTERNATIONAL GMBH: SWOT ANALYSIS

FIGURE 20 AMGEN INC..: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 AMGEN INC..: SWOT ANALYSIS

FIGURE 22 PROTALIX BIOTHERAPEUTICS, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 PROTALIX BIOTHERAPEUTICS, INC.: SWOT ANALYSIS

FIGURE 24 RELIANCE LIFE SCIENCES PVT. LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 RELIANCE LIFE SCIENCES PVT. LTD.: SWOT ANALYSIS

FIGURE 26 MOMENTA PHARMACEUTICALS INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 MOMENTA PHARMACEUTICALS INC: SWOT ANALYSIS

FIGURE 28 CELGENE CORPORATION: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 CELGENE CORPORATION: SWOT ANALYSIS

FIGURE 30 REGENERON PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 REGENERON PHARMACEUTICALS: SWOT ANALYSIS

FIGURE 32 MERCK & CO. INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 33 MERCK & CO. INC: SWOT ANALYSIS